Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

American Society for Microbiology Provides 2020 Guidelines for Detection and Identification of Group B Streptococcus

Laura Filkins, Jocelyn R. Hauser, Barbara Robinson-Dunn, Robert Tibbetts, Bobby L. Boyanton, Paula Revell
Sandra S. Richter, Editor
Laura Filkins
aDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura Filkins
Jocelyn R. Hauser
bPublic Health Laboratory, DC Department of Forensic Sciences, Washington, DC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Robinson-Dunn
cBeaumont Health System, Royal Oak, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Tibbetts
dDepartment of Pathology, Henry Ford Health System, Detroit, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bobby L. Boyanton
eDepartment of Pathology, Arkansas Children’s Hospital, Little Rock, Arkansas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula Revell
fDepartment of Pediatrics, Baylor College of Medicine/Texas Children’s Hospital, Houston, Texas, USA
gDepartment Pathology and Immunology, Baylor College of Medicine/Texas Children’s Hospital, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paula Revell
Sandra S. Richter
bioMérieux
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.01230-20
  • Article
  • Info & Metrics
  • PDF
Loading

LETTER

Maternal colonization with group B Streptococcus (GBS) is a primary risk factor for early-onset-disease (EOD) GBS infection in infants, and intrapartum prophylaxis reduces neonatal infection. The guidelines for GBS screening and intrapartum prophylaxis were last revised in 2010. In 2019, the CDC transferred stewardship of the GBS laboratory testing recommendations to the American Society for Microbiology. For the complete laboratory guidelines for GBS screening specimen collection and handling, organism detection and identification, and antimicrobial susceptibility testing (AST), we direct readers to the 2020 Guidelines for the Detection and Identification of Group B Streptococcus (1). Here, we highlight updates found in the 2020 GBS laboratory guidelines.

In 2019, the American College of Obstetricians and Gynecologists recommended antepartum screening for GBS during 36 0/7 to 37 6/7 weeks of gestation, a change from 35 to 37 weeks (2). Seven percent of U.S. births occur at or after 41 weeks (3). Shifting specimen collection 1 week later lengthens the 5-week predictive window of GBS screening tests to 41 0/7 weeks.

Best laboratory practices for GBS screening have not changed substantially since 2010. In the 2020 guidelines, culture remains the backbone of GBS detection. Methods for the identification of candidate GBS isolates from culture have expanded over the last decade. While biochemical testing and latex agglutination are acceptable for GBS identification, protein-based identification is ideal for laboratories with a matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF) instrument. Advantageously, MALDI-TOF provides rapid and specific identification of Streptococcus agalactiae and enables its differentiation from group B antigen-agglutinating strains of Streptococcus halichoeri and Streptococcus pseudoporcinus, whose clinical significance in EOD is poorly understood (4). However, these identification methods, including MALDI-TOF, require an isolated organism, increasing the time to results compared to identification directly from enrichment broth.

GBS is predictably susceptible to penicillin and ampicillin, the primary antibiotics for intrapartum prophylaxis. For women with severe penicillin allergy, clindamycin is the preferred agent. However, Streptococcus agalactiae rates of resistance to macrolides and lincosamides can exceed 40%, necessitating AST on GBS isolated from women who are severely allergic to penicillin (5). Unless AST is automatically performed on all isolates, regardless of penicillin allergy status, a mechanism for clear communication to the laboratory must be established to identify which patients’ isolates require AST.

Nucleic acid amplification tests (NAATs) performed after organism enrichment in broth medium are acceptable for the detection and identification of GBS. Indeed, recent studies report comparable or enhanced GBS sensitivity by NAATs after enrichment compared to culture (6–8). However, we recommend that all laboratories performing NAATs maintain culture procedures to permit AST for appropriate isolates.

Finally, the 2020 laboratory guidelines do not endorse direct-from-specimen GBS NAATs. Without enrichment, GBS NAATs suffer from poor sensitivity and a low negative predictive value (9, 10). Recent reports suggest that direct-from-specimen NAATs may inform additional prophylaxis in some situations but should not replace antenatal testing and risk-based prophylaxis (11). Evidence-based studies are required to determine when, how, and if direct-from-specimen NAATs are clinically beneficial. Currently, best-practice laboratory testing for GBS from screening specimens necessitates broth enrichment prior to NAAT or subculture.

  • Copyright © 2020 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Filkins L,
    2. Hauser J,
    3. Robinson-Dunn B,
    4. Tibbetts R,
    5. Boyanton B,
    6. Revell P
    , on behalf of the American Society for Microbiology Clinical and Public Health Microbiology Committee, Subcommittee on Laboratory Practices. 2020. Guidelines for detection and identification of group B Streptococcus. American Society for Microbiology, Washington, DC. https://asm.org/Guideline/Guidelines-for-the-Detection-and-Identification-of.
  2. 2.↵
    Committee on Obstetric Practice. 2019. Prevention of early-onset group B streptococcal disease in newborns: ACOG committee opinion, number 782. Obstet Gynecol 134:e19–e40. doi:10.1097/AOG.0000000000003334.
    OpenUrlCrossRef
  3. 3.↵
    1. Martin JA,
    2. Osterman MJK,
    3. Kirmeyer SE,
    4. Gregory ECW
    . 2015. Measuring gestational age in vital statistics data: transitioning to the obstetric estimate. Natl Vital Stat Rep 64:1–20.
    OpenUrlPubMed
  4. 4.↵
    1. Salimnia H,
    2. Robinson-Dunn B,
    3. Gundel A,
    4. Campbell A,
    5. Mitchell R,
    6. Taylor M,
    7. Fairfax MR
    . 2019. Suggested modifications to improve the sensitivity and specificity of the 2010 CDC-recommended routine Streptococcus agalactiae screening culture for pregnant women. J Clin Microbiol 57:e00446-19. doi:10.1128/JCM.00446-19.
    OpenUrlFREE Full Text
  5. 5.↵
    1. Metcalf BJ,
    2. Chochua S,
    3. Gertz RE, Jr,
    4. Hawkins PA,
    5. Ricaldi J,
    6. Li Z,
    7. Walker H,
    8. Tran T,
    9. Rivers J,
    10. Mathis S,
    11. Jackson D,
    12. McGee L,
    13. Beall B
    , Active Bacterial Core Surveillance Team. 2017. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA. Clin Microbiol Infect 23:574.e7–574.e14. doi:10.1016/j.cmi.2017.02.021.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Shin JH,
    2. Pride DT
    . 2019. Comparison of three nucleic acid amplification tests and culture for detection of group B Streptococcus from enrichment broth. J Clin Microbiol 57:e01958-18. doi:10.1128/JCM.01958-18.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Hernandez DR,
    2. Wolk DM,
    3. Walker KL,
    4. Young S,
    5. Dunn R,
    6. Dunbar SA,
    7. Rao A
    . 2018. Multicenter diagnostic accuracy evaluation of the Luminex Aries real-time PCR assay for group B Streptococcus detection in Lim broth-enriched samples. J Clin Microbiol 56:e01768-17. doi:10.1128/JCM.01768-17.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Buchan BW,
    2. Faron ML,
    3. Fuller D,
    4. Davis TE,
    5. Mayne D,
    6. Ledeboer NA
    . 2015. Multicenter clinical evaluation of the Xpert GBS LB assay for detection of group B Streptococcus in prenatal screening specimens. J Clin Microbiol 53:443–448. doi:10.1128/JCM.02598-14.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Alfa MJ,
    2. Sepehri S,
    3. De Gagne P,
    4. Helawa M,
    5. Sandhu G,
    6. Harding GKM
    . 2010. Real-time PCR assay provides reliable assessment of intrapartum carriage of group B Streptococcus. J Clin Microbiol 48:3095–3099. doi:10.1128/JCM.00594-10.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Plainvert C,
    2. El Alaoui F,
    3. Tazi A,
    4. Joubrel C,
    5. Anselem O,
    6. Ballon M,
    7. Frigo A,
    8. Branger C,
    9. Mandelbrot L,
    10. Goffinet F,
    11. Poyart C
    . 2018. Intrapartum group B Streptococcus screening in the labor ward by Xpert GBS real-time PCR. Eur J Clin Microbiol Infect Dis 37:265–270. doi:10.1007/s10096-017-3125-2.
    OpenUrlCrossRef
  11. 11.↵
    1. Ramesh Babu S,
    2. McDermott R,
    3. Farooq I,
    4. Le Blanc D,
    5. Ferguson W,
    6. McCallion N,
    7. Drew R,
    8. Eogan M
    . 2018. Screening for group B Streptococcus (GBS) at labour onset using PCR: accuracy and potential impact—a pilot study. J Obstet Gynaecol 38:49–54. doi:10.1080/01443615.2017.1328490.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
American Society for Microbiology Provides 2020 Guidelines for Detection and Identification of Group B Streptococcus
Laura Filkins, Jocelyn R. Hauser, Barbara Robinson-Dunn, Robert Tibbetts, Bobby L. Boyanton, Paula Revell on behalf of the American Society for Microbiology Clinical and Public Health Microbiology Committee, Subcommittee on Laboratory Practices
Journal of Clinical Microbiology Dec 2020, 59 (1) e01230-20; DOI: 10.1128/JCM.01230-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
American Society for Microbiology Provides 2020 Guidelines for Detection and Identification of Group B Streptococcus
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
American Society for Microbiology Provides 2020 Guidelines for Detection and Identification of Group B Streptococcus
Laura Filkins, Jocelyn R. Hauser, Barbara Robinson-Dunn, Robert Tibbetts, Bobby L. Boyanton, Paula Revell on behalf of the American Society for Microbiology Clinical and Public Health Microbiology Committee, Subcommittee on Laboratory Practices
Journal of Clinical Microbiology Dec 2020, 59 (1) e01230-20; DOI: 10.1128/JCM.01230-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

EOD
GBS
early-onset disease
group B Streptococcus
intrapartum prophylaxis
screening

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X